A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC)

Saito, Junichi; Nakai, Yushi; Saijo, Yasuo; Nukiwa, Toshihiro; Koinumaru, Sadahiro; Matsuura, Yoshifumi; Aso, Noboru; Yamane, Yoshio; Tsukamoto, Tomei; Sayama, Tsuneo; Nakabayashi, Takehito

doi:10.1016/s0169-5002(00)00183-5

Cited by 16 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two independent studies with combination chemotherapy of cisplatin (CDDP) and oral 5-FU (UFT) demonstrated that the response rate for squamous cell carcinoma was higher than that for adenocarcinoma (48.3% vs 24.2%, and 71.4% vs 27.6%, respectively). 2,3 Based on the present study, the clinical trial of 5-FUbased chemotherapy for squamous cell carcinoma is warranted, both for the treatment of advanced metastatic disease and for surgical adjuvant therapy.…”

Section: Discussionmentioning

confidence: 97%

“…[1][2][3][4] Because 5-FU is a timedependent antimetabolic agent, the antitumor effect can be favorably exhibited by longterm contact with tumor cells. However, about 80% of systemically administered 5-FU is catalyzed by dihydropyrimidine dehydrogenase (DPD) in the liver, which is the first and rate-limiting enzyme of the 5-FU catalytic pathway.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues

Yano

Koga

Ninomiya

et al. 2002

International Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues

Yano

Koga

Ninomiya

et al. 2002

International Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…In addition, UFT in combination with cisplatin for advanced NSCLC compares very favorably to the most commonly used regimens for first-line treatment of NSCLC (2,8,9). Although UFT is not available in the United States, another oral fluoropyrimidine, capecitabine is available and commonly used instead of 5-fluorouracil (5-FU).…”

Section: Introductionmentioning

confidence: 99%

Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer

Kindwall‐Keller¹,

Otterson²,

Young³

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Based on the preclinical observation of upregulation of thymidine phosphorylase, the last enzymatic step in the conversion of capecitabine to 5-fluorouracil, by docetaxel along with good clinical tolerability of the combination of docetaxel and capecitabine using an optimized schedule in a previous phase I trial, we conducted this phase II study of this combination in patients with refractory or relapsed non --small cell lung cancer (NSCLC).Patients and Methods: Patients with NSCLC previously treated with at least one platinum-or paclitaxel-based regimen received docetaxel 36 mg/m 2 on days 1, 8, and 15 and capecitabine 625 mg/m 2 twice daily on days 5 to 18, every 4 weeks. The primary objective of the study was evaluation of progression-free survival (PFS) 26 weeks from initiation of treatment.Results: Thirty-six evaluable patients received 104 cycles of the combination. Severe toxicities were infrequent with only one patient requiring toxicity-related hospitalization. The 26-week PFS rate was 25% (95% confidence interval, 12-42) with an intent to treat median survival and 1-year survival rate of 9.1 months and 37%, respectively. Among 31 patients with measurable disease (Response Evaluation Criteria in Solid Tumors criteria), eight (26%; 95% confidence interval, 12-45) achieved partial responses.Conclusion: The combination of capecitabine and weekly docetaxel is well tolerated in previously treated patients with NSCLC. The relatively high 26-week PFS and 1-year survival, as well as the high response rate observed, encourages further evaluation of this regimen in NSCLC, either in randomized trials for refractory patients or as a potential treatment option for chemotherapy naive patients.

show abstract

“…The combination chemotherapy of UFT plus cisplatin has also been reported to be an effective treatment for advanced NCSLC. The combination chemotherapy consisting of a daily administration of UFT for 2 or 3 weeks and a bolus injection of cisplatin at the mid-cycle of the administration of UFT yields a response rate of 29-38%, and a median survival time of 10 -13 months (Ichinose et al, 1995(Ichinose et al, , 2000Saito et al, 2001).…”

mentioning

confidence: 99%

UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial

et al. 2005

View full text Add to dashboard Cite

A multi-institutional phase II trial was conducted to evaluate the efficacy and toxicity of combination chemotherapy consisting of gemcitabine and UFT, which is composed of tegafur and uracil, for non-small-cell lung cancer (NSCLC) patients. Patients with advanced NSCLC received an oral administration of UFT (tegafur 200 mg m À2 ) b.i.d. from days 1 to 14 and intravenous injection of gemcitabine 900 mg m À2 on days 8 and 15. This treatment was repeated every 4 weeks. A total of 44 patients were enrolled into this trial. The median age of all patients was 74 years, with 23 patients younger than 75 years and 21 patients with 75 years of age or older. A total of 18 patients (41%) achieved a partial response. The median survival time was 13.2 months and the 1-year survival rate was 59%. The most common grade 3 -4 toxicity was neutropenia (57%). The frequency of grade 3 nonhaematologic toxicities was less than 5%. In addition, no significant difference in the response, survival or toxicities was observed between the patients younger than and those older than 75 years of age. This combination chemotherapy demonstrated a promising effectiveness and acceptable toxicity in patients with advanced NSCLC, even in patients older than 75 years.

show abstract

A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC)

Cited by 16 publications

References 13 publications

Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues

Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues

Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer

UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial

Contact Info

Product

Resources

About